Among them, cimetidine has been associated with an increased risk of prostate cancer in individuals who used it daily for 10 years when compared to non-users, while short-term use has shown no such association, possibly due to its inhibition of dihydrotestosterone binding to androgen receptors, increased plasma estradiol concentrations, and elevated prolactin levels, a potential growth factor for prostate cancer 10. This evidence concerns the gene AR and Familial prostate cancer.